Pharmabiz4h
Pfizer’s sasanlimab in combo with BCG improves EFS in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer
Pfizer’s sasanlimab in combo with BCG improves EFS in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer: New York Monday, January 13, 2025, 13:00 Hrs [IST] ...
Pfizer: My Top Play In 2025 Using Dogs Of The Dow Strategy
Pfizer is expected to rebound in 2025 with growth stabilized and dividend growth to continue. Learn why PFE stock is a Buy.
The Independent on MSN1h
‘Game changer’ immunotherapy drug could lead to increased survival rates for bladder cancer patients
The study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or ...
‘Increased survival rates’ for bladder cancer patients given immunotherapy drug
Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name ...
Bladder cancer patients more likely to survive with new drug
Patients in the study with advanced bladder cancer had less risk of cancer progressing or returning when treated with ...
New cancer drug could be 'game changer' for survival rates after UK trials
A 'game-changer' study found advanced bladder cancer patients treated with the drug durvalumab were a third less likely to ...